| Targeting DNA methylation and EZH2 activity to overcome melanoma resistance to immunotherapy A Al Emran, A Chatterjee, EJ Rodger, JC Tiffen, SJ Gallagher, MR Eccles, ... Trends in immunology 40 (4), 328-344, 2019 | 183 | 2019 |
| Design of an epitope-based peptide vaccine against spike protein of human coronavirus: an in silico approach AR Oany, AA Emran, TP Jyoti Drug design, development and therapy, 1139-1149, 2014 | 125 | 2014 |
| Early detection of lung cancer risk using data mining K Ahmed, AA Emran, T Jesmin, RF Mukti, M Rahman, F Ahmed © 2013 Asian Pacific Journal of Cancer Prevention, 2013 | 103 | 2013 |
| Emerging roles of H3K9me3, SETDB1 and SETDB2 in therapy-induced cellular reprogramming J Torrano, A Al Emran, H Hammerlindl, H Schaider Clinical epigenetics 11, 1-14, 2019 | 64 | 2019 |
| Distinct histone modifications denote early stress-induced drug tolerance in cancer AA Emran Oncotarget (DOI :10.18632/oncotarget.23654), 1-17, 2017 | 60 | 2017 |
| EZH2 cooperates with DNA methylation to downregulate key tumor suppressors and IFN gene signatures in melanoma J Tiffen, SJ Gallagher, F Filipp, D Gunatilake, A Al Emran, C Cullinane, ... Journal of Investigative Dermatology 140 (12), 2442-2454. e5, 2020 | 52 | 2020 |
| Depression and quality of life among postmenopausal women in Bangladesh: a cross-sectional study MI Bashar, K Ahmed, MS Uddin, F Ahmed, AA Emran, A Chakraborty Journal of menopausal medicine 23 (3), 172, 2017 | 33 | 2017 |
| Pretreatment innate cell populations and CD4 T cells in blood are associated with response to immune checkpoint blockade in melanoma patients MR Pirozyan, HM McGuire, AA Emran, HY Tseng, JC Tiffen, JH Lee, ... Frontiers in immunology 11, 372, 2020 | 25 | 2020 |
| Assessment of Menopausal Symptoms among Early and Late Menopausal Midlife Bangladeshi Women and Their Impact on the Quality of Life A Kawsar, J Papia, N Israt, A Farzana, AA Emran Journal of Menopausal Medicine 22 (1), 39-46, 2016 | 25 | 2016 |
| Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long‑term BRAF inhibition FP Madorsky Rowdo, A Barón, SJ Gallagher, P Hersey, AA Emran, ... International Journal of Oncology 56 (6), 1429-1441, 2020 | 22 | 2020 |
| A preliminary evaluation of cytotoxicity, antihyperglycemic and antinociceptive activity of Polygonum hydropiper L. ethanolic leaf extract AR Oany, AA Siddikey, MU Hossain, R Islam, AA Emran Clinical Phytoscience 2, 1-6, 2017 | 20 | 2017 |
| Co‐targeting bromodomain and extra‐terminal proteins and MCL1 induces synergistic cell death in melanoma HY Tseng, J Dreyer, AA Emran, D Gunatilake, M Pirozyan, C Cullinane, ... International journal of cancer 147 (8), 2176-2189, 2020 | 19 | 2020 |
| TP53 codon 72 polymorphisms and lung cancer risk in the Bangladeshi population MK Chowdhury, M Moniruzzaman, A Al Emran, MG Mostafa, RH Kuddus, ... Asian Pacific Journal of Cancer Prevention 16 (8), 3493-3498, 2015 | 19 | 2015 |
| Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS-Mutant Cancers H Hammerlindl, D Ravindran Menon, S Hammerlindl, AA Emran, ... Clinical Cancer Research 24 (5), 1090-1102, 2018 | 18 | 2018 |
| Lysine demethylases: promising drug targets in melanoma and other cancers G Punnia-Moorthy, P Hersey, AA Emran, J Tiffen Frontiers in Genetics 12, 680633, 2021 | 17 | 2021 |
| Magnolol induces cell death through PI3K/Akt‐mediated epigenetic modifications boosting treatment of BRAF‐ and NRAS‐mutant melanoma AA Emran, BR Chinna Chowdary, F Ahmed, H Hammerlindl, A Huefner, ... Cancer Medicine 8 (3), 1186-1196, 2019 | 17 | 2019 |
| Study of the female sex survival advantage in melanoma—a focus on X-linked epigenetic regulators and immune responses in two cohorts AA Emran, J Nsengimana, G Punnia-Moorthy, U Schmitz, SJ Gallagher, ... Cancers 12 (8), 2082, 2020 | 15 | 2020 |
| Commonly integrated epigenetic modifications of differentially expressed genes lead to adaptive resistance in cancer AA Emran, DM Marzese, DR Menon, H Hammerlindl, F Ahmed, E Richtig, ... Epigenomics 11 (7), 732-737, 2019 | 14 | 2019 |
| Repurposing melanoma chemotherapy to activate inflammasomes in the treatment of BRAF/MAPK inhibitor resistant melanoma F Ahmed, HY Tseng, A Ahn, D Gunatilake, S Alavi, M Eccles, H Rizos, ... Journal of Investigative Dermatology 142 (5), 1444-1455. e10, 2022 | 13 | 2022 |
| Do innate killing mechanisms activated by inflammasomes have a role in treating melanoma? AA Emran, HY Tseng, MC Coleman, J Tiffen, S Cook, HM McGuire, ... Pigment cell & melanoma research 33 (5), 660-670, 2020 | 13 | 2020 |
K. Ahmed, SMIEEEDept. of ECE, University of Saskatchewan, Canada; Associate Professor, Dept. of ICT, MBSTU, BDVerified email at mbstu.ac.bd
